Table 1 Patient and treatment characteristics
Variable | All patients | CTP A | CTP B |
|---|---|---|---|
No. (%) | No. (%) | No. (%) | |
No. of patients | 47 (100%) | 28 (60%) | 19 (40%) |
Age(years) | |||
 Median (range) | 69 (29–84) | 70 (45–84) | 69 (29–83) |
BCLC stage | |||
 B | 23 (49%) | 14 (50%) | 9 (47%) |
 C | 24 (51%) | 14 (50%) | 10 (53%) |
CTP score | |||
A | 28 (60%) | Â | Â |
 A5 | 16 (34%) | 16 |  |
 A6 | 12 (26%) | 12 |  |
B | 19 (40%) | Â | Â |
 B7 | 10 (21%) |  | 10 |
 B8 | 6 (13%) |  | 6 |
 B9 | 3 (6 %) |  | 3 |
Underlying liver disease | 41 (87%) | Â | Â |
 Hepatitis B | 4 (9%) | 3 (11%) | 1 (5%) |
 Hepatitis C | 6 (13%) | 3 (11%) | 3 (16%) |
 Alcohol related | 24 (51%) | 11 (39%) | 12 (63%) |
 NASHa | 6 (13%) | 5 (18%) | 2 (11%) |
 Primary biliary cirrhosis | 1 (2%) | 1 (7%) | 0 (0%) |
 None | 6 (13%) | 5 (18%) | 1 (5%) |
Previous treatmentsg | |||
 Surgery | 9 (19%) | 8 (29%) | 4 (21%) |
 TACEb | 34 (72%) | 21 (75%) | 13 (68%) |
 RFAc | 5 (11%) | 5 (18%) | 1 (5%) |
 Sorafenib | 10 (21%) | 8 (29%) | 2 (11%) |
 SIRTd | 2 (4%) | 2 (7%) | 0 (0%) |
 SBRTe | 7 (15%) | 2 (7%) | 3 (16%) |
Tumor vascular thrombosis | 13 (28%) | 5 (18%) | 8 (42%) |
Extrahepatic disease | 9 (19%) | 6 (21%) | 3 (16%) |
Multiple lesions at baseline | 39 (83%) | 24 (86%) | 15 (79%) |
GTV volumef | |||
 Median (IQR) cm3 | 77 (37–229) | 69 (35–214) | 108 (38–268) |
Diameter of the lesionsf | |||
 Media(IQR) cm | 7 (5–10) | 7 (4–10) | 8 (5–10) |
Liver Volume | |||
 Median (range) cm3 | 1654 (1384–2230) | 1492 (1340–2277) | 1819 (1554–1997) |
Prescription dose (Gy)f | |||
 Median (IQR) | 45 (38–48) | 45 (38–48) | 45 (44–50) |
Dmax | |||
 Median (IQR) | 53 (49–59) | 54 (52–59) | 51 (48–58) |
D95% | |||
 Median (IQR) | 45 (38–48) | 45 (37–48) | 45 (44–50) |
EQD210Â prescribed (Gy)f | |||
 Median (IQR) | 63 (51–75) | 56 (50–71) | 71 (56–85) |
EQD210 Dmax | |||
 Median (IQR) | 86 (62–104) | 91 (62–104) | 82 (61–99) |
EQD210 D95% | |||
 Median (IQR) | 60 (52–76) | 56 (48–72) | 71 (56–85) |
BED10prescribed (Gy)f | |||
 Median (IQR) | 76 (62–86) | 67 (61–85) | 86 (67–102) |
BED10 Dmax | |||
 Median (IQR) | 102 (75–125) | 109 (75–125) | 99 (73–115) |
BED10 D95% | |||
 Median (IQR) | 72 (62–91) | 67 (57–86) | 86 (67–102) |
Mean liver dose (Gy) | |||
 Median (IQR) | 17.9 (8.7–25) | 19 (9.8–25) | 16.5 (7.8–22) |
EQD22, mean liver dose | |||
 Median (IQR) | 16.5 (9.5–23) | 17.2 (9–23.5) | 15.6 (8.5–20.5) |